Description
CJC-1295 (No DAC), also known as Modified GRF (1-29), is a synthetic analog of growth hormone-releasing hormone (GHRH). It is designed to stimulate the pituitary gland to promote the body’s natural pulsatile release of growth hormone while improving stability compared to native GHRH.
Potential Areas of Research
Current research has explored CJC-1295 (No DAC) for its potential to:
- Support endogenous growth hormone secretion
- Increase circulating IGF-1 levels
- Investigate sleep-related growth hormone pulses
- Support recovery and tissue repair mechanisms
- Explore age-related changes in growth hormone physiology
- Study body composition and metabolic regulation
Mechanism of Action
CJC-1295 (No DAC) binds to growth hormone-releasing hormone (GHRH) receptors within the anterior pituitary, stimulating the natural release of endogenous growth hormone. Unlike exogenous recombinant human growth hormone (somatropin), CJC-1295 relies on an intact pituitary gland and supports physiologic GH secretion rather than directly supplying growth hormone.
The “No DAC” formulation has a relatively short duration of action, allowing it to more closely mimic the body’s natural pulsatile GH release compared to long-acting GHRH analogs.
Research Status
CJC-1295 (No DAC) remains an investigational peptide and has not been approved by the U.S. FDA for the treatment of growth hormone deficiency or other medical conditions. Research has demonstrated increases in growth hormone and IGF-1 following administration, but additional clinical studies are needed to establish long-term safety and efficacy across broader populations.
Product Information
- High-purity lyophilized peptide
- Manufactured under strict quality standards
- Intended for laboratory and research use only
Reviews
There are no reviews yet.